Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSI: Therapeutic Interventions in AML and High Risk MDS Undergoing Allo-SCT
NCT04217278Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jan 2020
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cytarabine, thiotepa in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Birmingham. Started Jan 2020; status: active, not recruiting.
02
Drugs
cytarabinethiotepa
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04217278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217278.